|
MART-1 (24-33(34))
|
|
|
|
MART-1 (1-20)
|
|
|
|
MAGE-12 (114-127)
|
|
|
|
MAGE-2 (127-136)
|
|
|
|
Leukocyte Proteinase-3 (169-177)
|
|
|
|
MAGE-1 (278-286)
|
|
|
|
MAGE-1 (62-70)
|
|
|
|
MAGE-1 (268-282)
|
|
|
|
lymphocyte antigen 6 complex locus K (114-133)
|
|
|
|
MAGE-1 (222-231)
|
|
|
|
MAGE-1 (96-104)
|
|
|
|
MAGE-2 (157-166)
|
|
|
|
lymphocyte antigen 6 complex locus K (61-84)
|
|
|
|
MAGE-1 (289-298)
|
|
|
|
Lengsin (270-279)
|
|
|
|
MAGE-12 (170-178)
|
|
|
|
MAGE-3 (111-125)
|
|
|
|
L-Homocarnosine dihydrochloride
|
|
1807885-26-2
|
|
Mammaglobin-A (23-31)
|
|
|
|
MARK Substrate
|
|
847991-34-8
|
|
MART-1 (100-111)
|
|
|
|
Mammaglobin-A precursor (2-10)
|
|
|
|
MAPK/MAK/MRK overlapping kinase (352-360)
|
|
|
|
Mammaglobin-A precursor (83-92)
|
|
|
|
MAGE-2 (156-164)
|
|
|
|
MAGE-2 (212-220)
|
|
|
|
MAPK/MAK/MRK overlapping kinase (32-40)
|
|
|
|
Mammaglobin-A precursor (66-74)
|
|
|
|
MAGE-6 (290-298)
|
|
|
|
MAGE-3 (97-105)
|
|
|
|
MAGE-6 (293-301)
|
|
|
|
MAGE-9 (223-231)
|
|
|
|
MART-1 (100-116)
|
|
|
|
MAPK/MAK/MRK overlapping kinase (11-20)
|
|
|
|
MAGE-1 (281-292)
|
|
|
|
MAGE-4 (156-163)
|
|
|
|
MAGE-3 (168-176)
|
|
|
|
MAGE-4 (230-239)
|
|
|
|
MAGE-3 (113-121)
|
|
|
|
MAGE-3 (167-176)
|
|
|
|
MAGE-3 (161-175)
|
|
|
|
MAGE-5 (5-12)
|
|
|
|
MAGE-1 (90-104)
|
|
|
|
MAGE-3 (114-122)
|
|
|
|
MAGE-6 (168-176)
|
|
|
|
MAGE-3 (119-134)
|
|
|
|
MAGE-3 (281-295)
|
|
|
|
MAGE-4 (143-151)
|
|
|
|
MAGE-3 (191-205)
|
|
|
|
MAGE-6 (121-134)
|
|
|
|
MAGE-3 (143-151)
|
|
|
|
MAGE-3 (149-160)
|
|
|
|
MAGE-3 (111-126)
|
|
|
|
MAGE-1 (102-112)
|
|
|
|
lymphocyte antigen 6 complex locus K (119-128)
|
|
|
|
LPGAT1 (262-270)
|
|
|
|
L-lactate dehydrogenase A chain (254-265)
|
|
|
|
Mammaglobin-A precursor (32-40)
|
|
|
|
LXW7
|
|
1313004-77-1
|
|
M-2420
|
|
310427-95-3
|
|
MART-1 (100-114)
|
|
|
|
MAGE-3 (243-258)
|
|
|
|
MAGE-3 (112-120)
|
|
|
|
MAGE-3 (267-282)
|
|
|
|
MAGE-4 (169-177)
|
|
|
|
Melanoma-associated antigen C1 (1083-1091)
|
|
|
|
Melanoma-associated antigen C2 (42-50)
|
|
|
|
Melanoma antigen preferentially expressed in tumors (142-151)
|
|
|
|
Melanoma-associated antigen C2 (191-200)
|
|
|
|
Melanoma-associated antigen C1 (450-458)
|
|
|
|
Melanoma antigen preferentially expressed in tumors (300-309)
|
|
|
|
Melanoma-associated antigen C1 (779-787)
|
|
|
|
Melanoma-associated antigen C1 (959-968)
|
|
|
|
Melanoma-associated antigen C2 (307-315)
|
|
|
|
Melanoma-associated antigen C2 (43-57)
|
|
|
|
Melanoma antigen preferentially expressed in tumors (301-309)
|
|
|
|
Melanoma-associated antigen C2 (336-344)
|
|
|
|
Melanoma-associated antigen C1 (137-149)
|
|
|
|
Melanoma antigen preferentially expressed in tumors (425-433)
|
|
|
|
MAGE-10 (254-262)
|
|
|
|
MAGE-1 (230-238)
|
|
|
|
MAGE-12 (127-141)
|
|
|
|
MAGE-10 (290-298)
|
|
|
|
Melanoma antigen preferentially expressed in tumors (100-108)
|
|
|
|
melanoma-overexpressed antigen 1 (11-23)
|
|
|
|
MART 1 peptide (1-10)
|
|
|
|
MART-1 (51-73)
|
|
|
|
Matrix protein 1 (27-35)
|
|
|
|
MART-1 (97-116)
|
|
|
|
Melanocyte protein Pmel 17 precursor (40-57)
|
|
|
|
Mammaglobin-A precursor (4-12)
|
|
|
|
Melanoma antigen gp100 (280-288)
|
|
|
|
Melanocyte protein Pmel 17 precursor (46-57)
|
|
|
|
Melanocyte protein Pmel 17 precursor (45-57)
|
|
|
|
MART-1 (32-40)
|
|
|
|
MART-1 (91-110)
|
|
|
|
Melanocyte protein Pmel 17 precursor (44-57)
|
|
|
|
Matrilysin (96-107)
|
|
|
|
MART-1 (51-61)
|
|
|
|
Matrix protein 1 (229-237)
|
|
|